Increased risk of hepatotoxicity w/ acetaminophen. May decrease adrenocorticoid effects of adrenocorticoids, glucocorticoid, & mineralocorticoid. May stimulate hepatic metabolism of aminophylline, oxtriphylline & theophylline. Decreased serum conc & elimination t½
of anticoagulants, coumarin & indandione-derivatives. Increased metabolism of anticovulsants especially clonazepam, primidone, valproic acid. Increased risk of congenital defects w/ other anticonvulsants. Enhanced CNS depressant effects & decreased anticonvulsant effect w/ TCAs, haloperidol, loxapine, maprotiline, molindone, phenothiazide, pimozide, thioxanthenes. Increased risk of carbamazepine-induced osteopenia w/ carbonic anhydrase inhibitors. May potentiate antidiuretic effect of chlorpropamide, clofibrate, desmopressin, lypressin, posterior pituitary, thiazide diuretics. Increased plasma conc of cimetidine. Decreased effects of estrogen-containing oral contraceptive, cyclosporine, decarbazine, digitalis glycosides, disopyramide or estrogen (including estramustine, levothyroxine, maxiletine, quinitine). Inhibited metabolism w/ danazol, diltiazem & verapamil; erythromycin, troleandomycin; influenza virus vaccine; propoxyphene. May decrease plasma conc & elimination t½
of doxycycline. Increased risk of hepatotoxicity w/ enflurane, malothane, methoxyflurane. May induce metabolism of INH. May decrease the antidiuretic effect & increase neurotoxic side effects w/ lithium. Lowered plasma conc of mebendazole. Concurrent use w/ MAOIs (including furazolidone, pargyline & procarbazine) resulted in hyperpyretic crises, hypertensive crises, severe convulsions & death.